On solutions to a FitzHugh–Rinzel type model

Ricerche di Matematica - A ternary autonomous dynamical system of FitzHugh–Rinzel type is analyzed. The system, at start, is reduced to a nonlinear integro differential equation. The...     

A Variational Approach to the Maximization of Preferences Without Numerical Representation

Journal of Optimization Theory and Applications - We introduce a variational approach to study a maximization problem of preferences that cannot be represented by a utility function. In such...     

Anti-Cancer Effects of Carnosine—A Dipeptide Molecule

Background: Carnosine is a dipeptide molecule (β-alanyl-l-histidine) with anti-inflammatory, antioxidant, anti-glycation, and chelating properties. It is used in exercise physiology as a food supplement to increase performance; however, in vitro evidence suggests that carnosine may exhibit anti-cancer properties. Methods: In this study, we investigated the effect of carnosine on breast, ovarian, colon, and leukemic cancer cell proliferation. We further examined U937 promonocytic, human myeloid leukemia cell phenotype, gene expression, and cytokine secretion to determine if these are linked to carnosine’s anti-proliferative properties. Results: Carnosine (1) inhibits breast, ovarian, colon, and leukemic cancer cell proliferation; (2) upregulates expression of pro-inflammatory molecules; (3) modulates cytokine secretion; and (4) alters U937 differentiation and phenotype. Conclusion: These effects may have implications for a role for carnosine in anti-cancer therapy.     

A Novel [OSSO]-Type Chromium(III) Complex as a Versatile Catalyst for Copolymerization of Carbon Dioxide with Epoxides

A new chromium(III) complex, bearing a bis-thioether-diphenolate [OSSO]-type ligand, was found to be an efficient catalyst in the copolymerization of CO₂ and epoxides to achieve poly(propylene carbonate), poly(cyclohexene carbonate), poly(hexene carbonate) and poly(styrene carbonate), as well as poly(propylene carbonate)(cyclohexene carbonate) and poly(propylene carbonate)(hexene carbonate) terpolymers.     

The maximum number of columns in supersaturated designs with

Cheng and Tang [Biometrika, 88 (2001), pp. 1169–1174] derived an upper bound on the maximum number of columns that can be accommodated in a two‐symbol supersaturated design (SSD) for a given number of rows () and a maximum in absolute value correlation between any two columns (). In particular, they proved that for (mod ) and . However, the only known SSD satisfying this upper bound is when . By utilizing a computer search, we prove that for , and . These results are obtained by proving the nonexistence of certain resolvable incomplete blocks designs. The combinatorial properties of the RIBDs are used to reduce the search space. Our results improve the lower bound for SSDs with rows and columns, for , and . Finally, we show that a skew‐type Hadamard matrix of order can be used to construct an SSD with rows and columns that proves . Hence, we establish for and for all (mod ) such that . Our result also implies that when is a prime power and (mod ). We conjecture that for all and (mod ), where is the maximum number of equiangular lines in with pairwise angle .     

Enantioselective analysis of venlafaxine and its active metabolites: A review on the separation methodologies

Venlafaxine (VFX) is a serotonin and norepinephrine reuptake inhibitor chiral drug used in therapy as an antidepressant in the form of a racemate consisting of R‐ and S‐VFX. The two enantiomers of VFX exhibit different pharmacological activities: R‐VFX inhibits both norepinephrine and serotonin synaptic reuptake, whereas S‐VFX inhibits only the serotonin one. R‐ and S‐VFX are metabolized in the liver to the respective R‐ and S‐O‐desmethylvenlafaxine (ODVFX), R‐ and S‐N‐desmethylvenlafaxine (NDVFX), and R‐ and S‐N,O‐didesmethylvenlafaxine (NODVFX). The pharmacological profile of ODVFX is close to that of VFX, whereas the other two chiral metabolites (NDVFX and NODVFX) have lower affinity for the receptor sites. The pharmacokinetics of the VFX enantiomers appear stereoselective, including the metabolism process. In the past 20 years, several studies describing the enantioselective analysis of R‐ and S‐VFX in pharmaceutical formulations and its chiral metabolites in biological matrices were published. These methods encompass liquid chromatography coupled with UV detection, mass spectrometry, or tandem mass spectrometry, and capillary electrophoresis. This paper reviews the published methods used for the determination of the individual enantiomers of VFX and its chiral metabolites in different matrices.